-

Carlsmed aprevo® Wins Spine Technology Award

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed announced today that aprevo® has been recognized by Orthopedics This Week with the prestigious Spine Technology Award. This award was presented at a ceremony today at the North American Spine Society (NASS) meeting in Boston. The award is given annually to exemplary and innovative spine surgery products that improve spine care, as judged by a panel that includes leading spine surgeons. Early clinical data supporting aprevo® is being presented at NASS during the Innovative Technologies Session.

“The Carlsmed team is honored to accept this award from Orthopedics This Week for our breakthrough aprevo® technology,” said Mike Cordonnier, CEO of Carlsmed. “Our mission is to provide broad access to this technology for patients suffering from debilitating spinal disorders.”

The aprevo® patient-specific interbody fusion devices are made possible by Carlsmed’s proprietary Data to Device™ digital technologies. For each aprevo® patient, a personalized surgical plan is developed preoperatively and presented to the surgeon to achieve the optimal spinal alignment target. Upon approval of the plan, unique interbody devices are created for the patient to address their specific pathology.

"By intentionally creating implants to fit a patient's own bone, we can start to realize the potential of personalized medicine and its benefits to each individual patient,” says Vijay Yanamadala, M.D., neurosurgeon and Director of Spinal Deformity Surgery at Hartford HealthCare. “My goal is for the aprevo® surgery to be the last spine surgery that a patient will ever need.”

The aprevo® patient specific interbody fusion devices are currently 510(k) cleared by the FDA for commercial use in the US for anterior, lateral and transforaminal surgical approaches.

About Carlsmed
Carlsmed’s mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The company’s aprevo® devices are designed to improve the standard of care for the surgical treatment of adult patients with spinal malalignment. Carlsmed uses patient data and proprietary digital technologies to create optimal surgical plans and personalized aprevo® spine fusion devices to align with the surgeon’s goals for each patient.

For more information, visit carlsmed.com or contact us at info@carlsmed.com.

Contacts

Jodi Coe
760-521-0167

Carlsmed


Release Versions

Contacts

Jodi Coe
760-521-0167

More News From Carlsmed

Carlsmed Announces FDA Clearance for aprevo® Cervical Breakthrough Fusion Device

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, Inc. (“Carlsmed” or the “Company”) a MedTech company pioneering AI-enabled personalized spine surgery, today announced FDA 510(k) clearance for the aprevo® Cervical ACDF Interbody System. This milestone underscores Carlsmed’s commitment to advancing patient-specific spine surgery solutions that enhance outcomes and surgical precision. The FDA previously granted Breakthrough Device designation for Carlsmed’s aprevo® technology for the treatment of pat...

Carlsmed Launches Cutting-Edge Digital Production Line, Revolutionizing Spine Surgery

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, a commercial-stage medical technology company and pioneer of the personalized spine surgery market, today announced the successful launch of its state-of-the-art digital production line. This innovative technology will enable the company to deliver its aprevo® personalized spinal fusion implants to hospitals in less than ten days. “This advancement is more than just a technical achievement,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “The re...

Carlsmed Adds Industry Veteran, Kevin O’Boyle, to Board of Directors

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, the leader in personalized spine surgery, announced that Kevin O’Boyle has joined its Board of Directors and will serve as the Chair of the Audit Committee. Mr. O’Boyle previously served as a director of seven publicly traded companies, including Wright Medical Group (WMGI), GenMark Diagnostics (GNMK) and Zeltiq (ZLTQ). In addition to Carlsmed, he currently serves on the board of Nevro (NVRO). Mr. O’Boyle has over 20 years of executive management exp...
Back to Newsroom